MIRATI THERAP sees an upgrade to Neutral thanks to a better star rating, but the title remains unattractive
The independent financial analyst theScreener just awarded an improved star rating to MIRATI THERAP (CA), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as moderately risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Neutral; the title, however, remains unattractive. As of the analysis date March 4, 2022, the closing price was USD 83.01 and its target price was estimated at USD 78.86.Mirati Therapeutics is a clinical-stage oncology company developing product candidates to address the genetic and immunological promoters of cancer. The company's KRAS inhibitor program is focused on developing inhibitors of KRAS mutations and includes one clinical candidate and a preclinical program. The company also has additional preclinical programs which include product candidates designed to address mutations and tumors where few treatment options exist. The company's clinical and preclinical programs consist of two product candidates: sitravatinib, a multi-kinase inhibitor and MRTX849, a KRAS G12C inhibitor. The company has several discovery programs, including a preclinical program for a KRAS G12D inhibitor.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.